<DOC>
	<DOC>NCT01505491</DOC>
	<brief_summary>This trial will investigate the pharmacokinetics, safety and tolerability of BI 695501 and to establish pharmacokinetic equivalence of BI 695501 to adalimumab.</brief_summary>
	<brief_title>Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criteria: 1. Healthy males 2. Body mass index (BMI) =18.5 to =29.9 kg/m2 Exclusion criteria: 1. Any clinically relevant abnormal finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance 2. Any evidence of a clinically relevant previous or concomitant disease as judged by the investigator. 3. Chronic or relevant acute infections. A negative result for Human Immunodeficiency Virus, Hepatitis B and Hepatitis C testing is required for participation. 4. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) 5. Intake of prescribed or overthecounter drugs with a long halflife (&gt;24 hours) within at least one month or less than 5 halflives of the respective drug prior to administration or during the trial 6. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day) 7. Inability to refrain from smoking during days of confinement at the study center 8. Alcohol abuse (average more than 30 g/day) 9. Current drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>